Glenmark Pharmaceuticals Ltd - Company Profile
Powered by
All the data and insights you need on Glenmark Pharmaceuticals Ltd in one report.
- Save hours of research time and resources with
our up-to-date Glenmark Pharmaceuticals Ltd Strategy Report
- Understand Glenmark Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Glenmark Pharmaceuticals Catalyst Calendar
Proactively evaluate Glenmark Pharmaceuticals Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Glenmark Pharmaceuticals Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
15 Feb 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
31 Jan 2020 | Phase III Trial Initiation | Glenmark Pharmaceuticals Ltd | GLENMARK | (remogliflozin etabonate + vildagliptin) | Metabolic Disorders | Type 2 Diabetes | Clinical Trial Registry |
01 Dec 2019 | Phase I Trial Initiation | Glenmark Pharmaceuticals Ltd | GLENMARK | ISB-1342 | Oncology | Solid Tumor | Company Press Release |
01 Dec 2019 | Phase I Trial Initiation | Glenmark Pharmaceuticals Ltd | GLENMARK | ISB-1302 | Oncology | Breast Cancer; Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer